Literature DB >> 22583156

Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia.

J Burgos1, V Falcó, A Borrego, R Sordé, M N Larrosa, X Martinez, A M Planes, A Sánchez, M Palomar, J Rello, A Pahissa.   

Abstract

The introduction of the 7-valent pneumococcal conjugate vaccine in children has led to a change in the pattern of pneumococcal serotypes causing pneumococcal disease. The aim of this study was to compare the clinical presentation and outcome of invasive pneumococcal pneumonia (IPP) in adults between the pre and post-vaccine era. We have conducted an observational study of all adults hospitalized with IPP, from 1996 to 2001 (pre-vaccine period), and from 2005 to 2009 (post-vaccine period). Incidence, serotype distribution and clinical data were compared between both periods. A total of 653 episodes of IPP were diagnosed. The overall incidence of IPP increased from 14.2 to 17.9 cases per 100 000 population-year (p 0.003). In the post-vaccine period IPP caused by vaccine serotypes decreased (-36%; 95% CI, -52 to -15) while IPP caused by non-vaccine serotypes increased (71%; 95% CI, 41-106). IPP in the post-vaccine period was associated with higher rates of septic shock (19.1% vs. 31.1%, p <0.001). Among patients aged 50-65 years there was a trend towards a greater proportion of case-fatalities (11.6-23.5%, p 0.087). Independent risk factors for septic shock were IPP caused by serotype 3 (OR 2.38; 95% CI, 1.16-4.87) and serotype 19A (OR 6.47, 95% CI, 1.55-27). Serotype 1 was associated with a lower risk of death (OR 0.1; 95% CI, 0.01-0.78). In conclusion, the incidence of IPP in the post-vaccine period has increased in our setting, it is caused mainly by non-vaccine serotypes and it is associated with higher rates of septic shock.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22583156     DOI: 10.1111/j.1469-0691.2012.03895.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  16 in total

1.  A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia.

Authors:  Ryuta Uraki; Zhenyu Piao; Yukihiro Akeda; Kiyoko Iwatsuki-Horimoto; Maki Kiso; Makoto Ozawa; Kazunori Oishi; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2015-06-29       Impact factor: 5.226

2.  Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial.

Authors:  Yujia Kong; Wei Zhang; Zhiwei Jiang; Ling Wang; Chanjuan Li; Yanping Li; Jielai Xia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Mechanistic Understanding of Lung Inflammation: Recent Advances and Emerging Techniques.

Authors:  Chrysi Keskinidou; Alice G Vassiliou; Ioanna Dimopoulou; Anastasia Kotanidou; Stylianos E Orfanos
Journal:  J Inflamm Res       Date:  2022-06-15

4.  Factors associated with pneumococcal polysaccharide vaccination of the elderly in Spain: A cross-sectional study.

Authors:  Angela Domínguez; Núria Soldevila; Diana Toledo; Pere Godoy; Núria Torner; Luis Force; Jesús Castilla; José María Mayoral; Sonia Tamames; Vicente Martín; Mikel Egurrola; Francisco Sanz; Jenaro Astray
Journal:  Hum Vaccin Immunother       Date:  2016-04-11       Impact factor: 3.452

5.  Isolation site influences virulence phenotype of serotype 14 Streptococcus pneumoniae strains belonging to multilocus sequence type 15.

Authors:  Zarina Amin; Richard M Harvey; Hui Wang; Catherine E Hughes; Adrienne W Paton; James C Paton; Claudia Trappetti
Journal:  Infect Immun       Date:  2015-09-28       Impact factor: 3.441

6.  Bacteraemic and non-bacteraemic/urinary antigen-positive pneumococcal community-acquired pneumonia compared.

Authors:  S P van Mens; A M M van Deursen; S C de Greeff; H E de Melker; L M Schouls; A van der Ende; M J M Bonten; E A M Sanders; B J M Vlaminckx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-01       Impact factor: 3.267

7.  Nasopharyngeal pneumococcal carriage rates among HIV-infected adults following widespread pediatric use of conjugate pneumococcal vaccine-13.

Authors:  Theresa D Feola; Cynthia A Bonville; Donald A Cibula; Sherly Jose; Geetha Nattanmai; Joseph B Domachowske; Manika Suryadevara
Journal:  Hum Vaccin Immunother       Date:  2016-05-24       Impact factor: 3.452

8.  Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Authors:  Adoración Navarro-Torné; Eva Agostina Montuori; Vasiliki Kossyvaki; Cristina Méndez
Journal:  Hum Vaccin Immunother       Date:  2021-06-09       Impact factor: 4.526

9.  The relevance of pneumococcal serotypes.

Authors:  Chamira Rodrigo; Wei Shen Lim
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

Review 10.  Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance.

Authors:  Joon Young Song; Moon H Nahm; M Allen Moseley
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.